Shopping Cart
Remove All
Your shopping cart is currently empty
LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $263 | - | In Stock | |
| 5 mg | $538 | - | In Stock | |
| 10 mg | $872 | - | In Stock | |
| 25 mg | $1,290 | - | In Stock | |
| 50 mg | $1,730 | - | In Stock |
| Description | LadiratuzumAb (hLIV22) is a humanized monoclonal antibody targeting LIV-1/ZIP6.LadiratuzumAb is a naked antibody to SGN-LIV1A and is capable of synthesizing an antibody-activated molecule coupling (ADC), SGN-LIV1A.LadiratuzumAb can be used for the prevention and treatment of breast cancer. |
| Synonyms | hLIV22 |
| Reactivity | Human |
| Verified Activity | Immobilized TARGET at 2 μg/mL (30 μL/well) can bind Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumAb) with the EC50 of 5.145 ng/mL. |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 146.96 kDa |
| Cas No. | 1629760-28-6 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.